137310.KS
SD BioSensor, Inc [137310.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
137310.KS Stock Summary
Top 137310.KS Correlated Resources
137310.KS
Top 10 Correlated ETFs
137310.KS
Top 10 Correlated Stocks
137310.KS
137310.KS Financial details
Company Rating
Buy
Market Cap
3263.62B
Income
1366.28B
Revenue
3178.37B
Book val./share
32589.42
Cash/share
-
Dividend
1966
Dividend %
6.14%
Employees
523
Optionable
No
Shortable
Yes
Earnings
-
P/E
2.37
Forward P/E
-
PEG
0.08
P/S
1.02
P/B
0.98
P/C
-
P/FCF
3.88
Quick Ratio
-
Current Ratio
6.31
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
26.78K
EPS next Y
-
EPS next Q
-
EPS this Y
72.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-30.67%
EPS Q/Q
23.91%
-
-
-
-
SMA20
8.23%
SMA50
5.59%
SMA100
-22.27%
Inst Own
-
Inst Trans
-
ROA
36%
ROE
50%
ROC
0.42%
Gross Margin
52%
Oper. Margin
44%
Profit Margin
43%
Payout
15%
Shs Outstand
101.14M
Shs Float
34.49M
-
-
-
-
Target Price
-
52W Range
25050.0-81000.0
52W High
-60.49%
52W Low
+27.74%
RSI
48.6
Rel Volume
0.63
Avg Volume
302.24K
Volume
189K
Perf Week
-3.03%
Perf Month
14.49%
Perf Quarter
-26.1%
Perf Half Y
-35.22%
-
-
-
-
Beta
-
-
-
Volatility
402.54%, 1929.55%
Prev Close
0.63%
Price
32000
Change
-4.19%
137310.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2021-12-31 |
|---|---|---|
| Revenue per share | 31.4K | |
| Net income per share | 11.41K | |
| Operating cash flow per share | 13.23K | |
| Free cash flow per share | 12.17K | |
| Cash per share | 20.31K | |
| Book value per share | 23.47K | |
| Tangible book value per share | 23.2K | |
| Share holders equity per share | 23.47K | |
| Interest debt per share | 272.79 | |
| Market cap | 5645.9B | |
| Enterprise value | 4789.27B | |
| P/E ratio | 5.3 | |
| Price to sales ratio | 1.93 | |
| POCF ratio | 4.57 | |
| PFCF ratio | 4.97 | |
| P/B Ratio | 2.58 | |
| PTB ratio | 2.58 | |
| EV to sales | 1.63 | |
| Enterprise value over EBITDA | 3.28 | |
| EV to operating cash flow | 3.88 | |
| EV to free cash flow | 4.22 | |
| Earnings yield | 0.19 | |
| Free cash flow yield | 0.2 | |
| Debt to equity | 0.01 | |
| Debt to assets | 0.27 | |
| Net debt to EBITDA | -0.59 | |
| Current ratio | 3.31 | |
| Interest coverage | 2.79K | |
| Income quality | 1.16 | |
| Dividend Yield | 0.01 | |
| Payout ratio | 0.05 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0.01 | |
| Intangibles to total assets | 0.01 | |
| Capex to operating cash flow | -0.08 | |
| Capex to revenue | -0.03 | |
| Capex to depreciation | -5.19 | |
| Stock based compensation to revenue | 0.01 | |
| Graham number | 77.63K | |
| ROIC | 0.61 | |
| Return on tangible assets | 0.36 | |
| Graham Net | 13.46K | |
| Working capital | 1798.11B | |
| Tangible asset value | 2165.36B | |
| Net current asset value | 1776.26B | |
| Invested capital | 0.01 | |
| Average receivables | 0 | |
| Average payables | 281.98B | |
| Average inventory | 345.4B | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 36.13 | |
| Days of inventory on hand | 87.08 | |
| Receivables turnover | 0 | |
| Payables turnover | 10.1 | |
| Inventory turnover | 4.19 | |
| ROE | 0.49 | |
| Capex per share | -1.06K |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 5.64K | 14.12K | 44.18K | 7.86K | 5.45K | |
| Net income per share | 2.32K | 4.15K | 15.1K | 3.36K | 4.17K | |
| Operating cash flow per share | 5.33K | 4.9K | 3.46K | 2.4K | 2.65K | |
| Free cash flow per share | 5.12K | 6.64K | 37.06 | 1.46K | 2.26K | |
| Cash per share | 0 | 60.31K | 0 | 17.79K | 0 | |
| Book value per share | 22.82K | 69.7K | 82.12K | 28.94K | 32.59K | |
| Tangible book value per share | 22.94K | 68.9K | 82.54K | 28.39K | 32.72K | |
| Share holders equity per share | 22.82K | 69.7K | 82.12K | 28.94K | 32.59K | |
| Interest debt per share | 0 | 799.18 | 125.19 | 367.62 | 106.56 | |
| Market cap | 4212.8B | 1756.79B | 1753.65B | 3929.18B | 2690.25B | |
| Enterprise value | 4212.8B | 900.17B | 1753.65B | 2572.67B | 2690.25B | |
| P/E ratio | 4.86 | 3.37 | 0.92 | 2.89 | 1.6 | |
| Price to sales ratio | 8 | 3.96 | 1.26 | 4.94 | 4.88 | |
| POCF ratio | 8.47 | 11.4 | 16.12 | 16.21 | 10.05 | |
| PFCF ratio | 8.82 | 8.42 | 1.51K | 26.6 | 11.79 | |
| P/B Ratio | 1.98 | 0.8 | 0.68 | 1.34 | 0.82 | |
| PTB ratio | 1.98 | 0.8 | 0.68 | 1.34 | 0.82 | |
| EV to sales | 8 | 2.03 | 1.26 | 3.24 | 4.88 | |
| Enterprise value over EBITDA | 14.06 | 5.51 | 2.66 | 5.38 | 5.4 | |
| EV to operating cash flow | 8.47 | 5.84 | 16.12 | 10.61 | 10.05 | |
| EV to free cash flow | 8.82 | 4.32 | 1.51K | 17.42 | 11.79 | |
| Earnings yield | 0.05 | 0.07 | 0.27 | 0.09 | 0.16 | |
| Free cash flow yield | 0.11 | 0.12 | 0 | 0.04 | 0.08 | |
| Debt to equity | 0 | 0.01 | 0 | 0.01 | 0 | |
| Debt to assets | 0.22 | 0.27 | 0.33 | 0.2 | 0.14 | |
| Net debt to EBITDA | 0 | -5.24 | 0 | -2.84 | 0 | |
| Current ratio | 4.08 | 3.31 | 2.63 | 4.12 | 6.31 | |
| Interest coverage | 0 | 1K | 157.48 | 1.55K | 27.23 | |
| Income quality | 2.3 | 1.18 | 0.23 | 0.71 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.03 | |
| Payout ratio | 0.01 | 0.01 | 0 | 0 | 0.17 | |
| Sales general and administrative to revenue | 0.13 | 0 | 0.04 | 0 | 0.11 | |
| Research and developement to revenue | 0 | 0.01 | 0 | 0.02 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0 | 0.02 | 0 | |
| Capex to operating cash flow | -0.04 | 0 | -0.99 | -0.39 | -0.15 | |
| Capex to revenue | -0.04 | 0 | -0.08 | -0.12 | -0.07 | |
| Capex to depreciation | -3.94 | 0 | -16.15 | -9.56 | -3.81 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Graham number | 34.54K | 80.69K | 167.01K | 46.79K | 55.27K | |
| ROIC | 0.15 | 0.07 | 0.24 | 0.12 | 0.09 | |
| Return on tangible assets | 0.08 | 0.04 | 0.12 | 0.09 | 0.11 | |
| Graham Net | -6.6K | 39.97K | -40.34K | 12.57K | -5.11K | |
| Working capital | 1840.02B | 1798.11B | 2032.32B | 2259.93B | 2631.93B | |
| Tangible asset value | 0 | 2165.36B | 0 | 2871.08B | 0 | |
| Net current asset value | 1821.8B | 1776.26B | 2008.13B | 2235.98B | 2610.86B | |
| Invested capital | 0 | 0.01 | 0 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 156.47B | 0 | 178.3B | 0 | |
| Average inventory | 0 | 381.51B | 0 | 438.57B | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 50.93 | 0 | 42.54 | 0 | |
| Days of inventory on hand | 0 | 122.73 | 0 | 104.64 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 1.77 | 0 | 2.12 | 0 | |
| Inventory turnover | 0 | 0.73 | 0 | 0.86 | 0 | |
| ROE | 0.1 | 0.06 | 0.18 | 0.12 | 0.13 | |
| Capex per share | -216.28 | 0 | -3.42K | -936.49 | -391.84 |
137310.KS Frequently Asked Questions
What is SD BioSensor, Inc stock symbol ?
SD BioSensor, Inc is a US stock and trading under the symbol 137310.KS
What is SD BioSensor, Inc stock quote today ?
SD BioSensor, Inc stock price is $32000 today.
Is SD BioSensor, Inc stock public?
Yes, SD BioSensor, Inc is a publicly traded company.
Company Profile
- Volume Average 302.24K
- Market Capitalization 3263.62B
- Employee 523
- Headquarters Suwon,US
- IPO Date 2021-07-16
-
Website
https://www.sdbiosensor.com 
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
